Skip to main content

Table 1 Clinical and laboratory features in 145 patients with chronic myelomonocytic leukemia

From: Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia

Age in years, median (range) 63(18–85)
Males; n (%) 98(68)
Hemoglobin g/L, median (range) 88.0(43.0–166.0)
WBC (109/L), median (range) 21.88(3.01–117.57)
ANC (109/L), median (range) 7.07(0.30–66.91)
AMC (109/L), median (range) 3.58(1.02–57.72)
Platelets (109/L), median (range) 78(4–1001)
FAB subtypes, n (%)  
Myelodysplastic, MD 51(35)
Myeloproliferative, MP 94(65)
WHO subtypes, n (%)  
CMML-1 84(58)
CMML-2 61(42)
Mutational status  
ASXL1, n (%) 65(45)
SETBP1, n (%) 26(18)
TET2, n (%) 47(32)
SRSF2, n (%) 42(29)
aAcute leukemic transformation; n (%) 18(14)
aDeaths; n (%) 71(56)
  1. aData of acute leukemic transformation and deaths were limited to 127 patients because of 15 cases of limited updating and 3 cases of transplantation